Main characteristics of participants from included studies
| Author and year of publication | Population | N (on PrEP/not on PrEP) | Gender and sexual orientation* | Age median (IQR)* |
| Berçot et al, 202132 | Asymptomatic MSM from the ANRS IPERGAY trial (which evaluated on-demand PrEP) that were enrolled in an RCT of PEP with doxycycline | 210 (210/0) | Men: 210 (MSM: 210) | 38 (32–46) |
| Bradley et al, 202033* | Asymptomatic MSM who were having a rectal swab for NG, CT and MG collected as part of their routine care (screening) | 742 (170/572) | Men: 739 (MSM: 739) Transgender: 3 | 31 (27–39) |
| Brin et al, 202234* | Patients vising the hospital for routine STI screening, possible STI symptoms or follow-up for PrEP or HIV infection | 5586 (207/5379) | Men: 3649 (MSM: NR) Women: 1884 Transgender: 8 | Women: 23 (21–28) Men: 29 (23–39) |
| Chambers et al, 201935* | Symptomatic MSM >16 years with NGU from an STI clinic | 103 (18/85) | Men: 103 (MSM: 103) | 30 (27–39) |
| Couldwell et al, 201836*† | Symptomatic and asymptomatic MSM attending a sexual health centre for STI testing | 508 (169/339) | Men: 508 (MSM: 508) | 33 (NR) |
| De Baetselier et al, 202237 | Symptomatic and asymptomatic MSM from the Be-PrEP-ared cohort study, in which STIs were tested every 3 months | 179 (179/0) | Men: 179 (MSM: 179) | NR |
| Deborde et al, 2019 and Ducours et al, 201938 39 | Patients on PrEP | 148 (148/0) | Men: 145 (MSM: 145) Woman: 1 Transgender: 2 | 35 (NR) |
| Guiraud et al, 202140* | Men from an STI clinic | 78 (16/62) | Men: 78 (MSM: 60) | 34 (20–58) |
| Herms et al, 202141* | Symptomatic and asymptomatic patients undergoing STI testing | 249 (13/236) | Men: 224 (MSM: 85) Women: 22 | Mean 34 (range 15–76) |
| Jansen et al, 202042* | Symptomatic and asymptomatic ≥18 years MSM | 2303 (283/2020) | Men: 2303 (MSM: 2303) | 39 (range 18–79) |
| McIver et al, 201943* | Men >16 years presenting symptoms of acute NGU | 588 (102/486) | Men: 588 (MSM: 306) | 30 (26–37) |
| Read et al, 2019* and Chua et al, 202144 45* | Asymptomatic MSM from the MnM Study that reported receptive anal sex in the preceding year | 1001 (142/859) 94 (14/80) | Men: 1001 (MSM: 1001) Men: 94 (MSM: 94) | 29 (24–34) 27 (23–32) |
| Richardson et al, 202146*† | MSM with symptomatic gonococcal urethritis | 184 (31/153) | Men: 184 (MSM: 109) | 31 (24–38) |
| Streeck et al, 202247* | MSM at the screening visit for the BRAHMS Study | 1043 (553/490) | Men: 1042 (MSM: 959) | 33 (28–39) |
| Van Praet et al, 201948 | MSM on PrEP screened for STIs | 131 (131/0) | Men: 131 (MSM: 131) | 40 (20–79) |
*For studies that also included not only individuals on PrEP.
†There is an overlap of participants between the studies of Couldwell et al and Richardson et al.
CT, Chlamydia trachomatis; MG, Mycoplasma genitalium; MSM, men who have sex with men; N, number of participants; NG, Neisseria gonorrhoeae; NGU, non-gonococcal urethritis; NR, not reported; PEP, post-exposure prophylaxis; PrEP, pre-exposure prophylaxis; RCT, randomised clinical trial; STI, sexually transmitted infection.